Loading...

Skip to main content

Call us on + 1 (800) 604-9114 for more information about our products

Looking for specific datasheet Manual/COA/MSDS?
Request a Manual/COA/MSDS

Interested to get a quote about our products?
Request a Quote

Immunohistochemistry (IHC) (Immunohistochemical analysis of paraffin-embedded human skeletal muscle tissue using MBS9202426 performed on the Leica® BOND RXm. Samples were incubated with primary antibody(1/500) for 1 hours at room temperature. A undiluted biotinylated CRF Anti-Polyvalent HRP Polymer antibody was used as the secondary antibody.)

Rabbit GC Polyclonal Antibody | anti-GBA antibody

GC Antibody (Center)

Gene Names
GBA; GCB; GBA1; GLUC
Reactivity
Human, mouse (Predicted Reactivity: Bovine, Pig)
Applications
Immunohistochemistry, Flow Cytometry, Functional Assay, Western Blot, ELISA
Purity
This antibody is purified through a protein A column, followed by peptide affinity purification.
Synonyms
GC; Polyclonal Antibody; GC Antibody (Center); Glucosylceramidase; Acid beta-glucosidase; Alglucerase; Beta-glucocerebrosidase; Beta-GC; D-glucosyl-N-acylsphingosine glucohydrolase; Imiglucerase; GBA; GLUC; anti-GBA antibody
Ordering
For Research Use Only!
Host
Rabbit
Reactivity
Human, mouse (Predicted Reactivity: Bovine, Pig)
Clonality
Polyclonal
Isotype
IgG
Specificity
This GC antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 337-365 amino acids from the Central region of human GC.
Purity/Purification
This antibody is purified through a protein A column, followed by peptide affinity purification.
Form/Format
Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide.
Sequence Positions
337-365
Applicable Applications for anti-GBA antibody
Immunohistochemistry (IHC) - Paraffin - Leica, Flow Cytometry (FC/FACS), Western Blot (WB), ELISA
Application Notes
IHC-P-Leica~~1:500
FC~~1:25
WB~~1:1000
Clone Names
RB21567
Function
Glucosylceramidase that catalyzes, within the lysosomal compartment, the hydrolysis of glucosylceramide/GlcCer into free ceramide and glucose (PubMed:9201993, PubMed:24211208). Thereby, plays a central role in the degradation of complex lipids and the turnover of cellular membranes (PubMed:27378698). Through the production of ceramides, participates to the PKC-activated salvage pathway of ceramide formation (PubMed:19279011). Also plays a role in cholesterol metabolism (PubMed:24211208, PubMed:26724485). May either catalyze the glucosylation of cholesterol, through a transglucosylation reaction that transfers glucose from glucosylceramide to cholesterol (PubMed:24211208, PubMed:26724485). The short chain saturated C8:0-GlcCer and the mono-unsaturated C18:0-GlcCer being the most effective glucose donors for that transglucosylation reaction (PubMed:24211208). Under specific conditions, may alternatively catalyze the reverse reaction, transferring glucose from cholesteryl-beta-D-glucoside to ceramide (PubMed:26724485). Finally, may also hydrolyze cholesteryl-beta-D-glucoside to produce D-glucose and cholesterol (PubMed:24211208, PubMed:26724485).
Cellular Location
Lysosome membrane; Peripheral membrane protein; Lumenal side. Note=Interaction with saposin-C promotes membrane association (PubMed:10781797). Targeting to lysosomes occurs through an alternative MPR-independent mechanism via SCARB2 (PubMed:18022370).
Preparation and Storage
Maintain refrigerated at 2-8 degree C for up to 2 weeks. For long term storage store at -20 degree C in small aliquots to prevent freeze-thaw cycles.

Immunohistochemistry (IHC)

(Immunohistochemical analysis of paraffin-embedded human skeletal muscle tissue using MBS9202426 performed on the Leica® BOND RXm. Samples were incubated with primary antibody(1/500) for 1 hours at room temperature. A undiluted biotinylated CRF Anti-Polyvalent HRP Polymer antibody was used as the secondary antibody.)

Immunohistochemistry (IHC) (Immunohistochemical analysis of paraffin-embedded human skeletal muscle tissue using MBS9202426 performed on the Leica® BOND RXm. Samples were incubated with primary antibody(1/500) for 1 hours at room temperature. A undiluted biotinylated CRF Anti-Polyvalent HRP Polymer antibody was used as the secondary antibody.)

Flow Cytometry (FC/FACS)

(Overlay histogram showing Hela cells stained with MBS9202426 (green line). The cells were fixed with 2% paraformaldehyde (10 min) and then permeabilized with 90% methanol for 10 min. The cells were then icubated in 2% bovine serum albumin to block non-specific protein-protein interactions followed by the antibody (MBS9202426, 1:25 dilution) for 60 min at 37ºC. The secondary antibody used was Goat-Anti-Rabbit IgG, DyLight® 488 Conjugated Highly Cross-Adsorbed at 1/200 dilution for 40 min at 37ºC. Isotype control antibody (blue line) was rabbit IgG1 (1ug/1x10^6 cells) used under the same conditions. Acquisition of >10, 000 events was performed.)

Flow Cytometry (FC/FACS) (Overlay histogram showing Hela cells stained with MBS9202426 (green line). The cells were fixed with 2% paraformaldehyde (10 min) and then permeabilized with 90% methanol for 10 min. The cells were then icubated in 2% bovine serum albumin to block non-specific protein-protein interactions followed by the antibody (MBS9202426, 1:25 dilution) for 60 min at 37ºC. The secondary antibody used was Goat-Anti-Rabbit IgG, DyLight® 488 Conjugated Highly Cross-Adsorbed at 1/200 dilution for 40 min at 37ºC. Isotype control antibody (blue line) was rabbit IgG1 (1ug/1x10^6 cells) used under the same conditions. Acquisition of >10, 000 events was performed.)

Western Blot (WB)

(All lanes : Anti-GC Antibody (Center) at 1:2000 dilution Lane 1: 293T/17 whole cell lysate Lane 2: Hela whole cell lysate Lane 3: LNCaP whole cell lysate Lane 4: MCF-7 whole cell lysate Lane 5: U-2OS whole cell lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 60 kDa Blocking/Dilution buffer: 5% NFDM/TBST.)

Western Blot (WB) (All lanes : Anti-GC Antibody (Center) at 1:2000 dilution Lane 1: 293T/17 whole cell lysate Lane 2: Hela whole cell lysate Lane 3: LNCaP whole cell lysate Lane 4: MCF-7 whole cell lysate Lane 5: U-2OS whole cell lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 60 kDa Blocking/Dilution buffer: 5% NFDM/TBST.)

Western Blot (WB)

(Western blot analysis of GC Antibody (Center) (Cat. #MBS9202426) in mouse lung tissue lysates (35ug/lane). GC (arrow) was detected using the purified Pab.)

Western Blot (WB) (Western blot analysis of GC Antibody (Center) (Cat. #MBS9202426) in mouse lung tissue lysates (35ug/lane). GC (arrow) was detected using the purified Pab.)
Related Product Information for anti-GBA antibody
GC is a protein that cleaves the beta-glucosidic linkage of glycosylceramide, an intermediate in glycolipid metabolism.
Product Categories/Family for anti-GBA antibody
References
Jamrozik,Z., et.al., J. Neurol. 257 (3), 459-460 (2010)
Mao,X.Y., et.al., Neurosci. Lett. 469 (2), 256-259 (2010)

NCBI and Uniprot Product Information

NCBI GI #
NCBI GeneID
NCBI GenBank Nucleotide #
UniProt Accession #
NCBI Official Full Name
glucosylceramidase isoform 1
NCBI Official Synonym Full Names
glucosidase, beta, acid
NCBI Official Symbol
GBA
NCBI Official Synonym Symbols
GCB; GBA1; GLUC
NCBI Protein Information
glucosylceramidase
UniProt Protein Name
Glucosylceramidase
Protein Family
UniProt Gene Name
GBA
UniProt Synonym Gene Names
GC; GLUC; Beta-GC
UniProt Entry Name
GLCM_HUMAN

NCBI Description

This gene encodes a lysosomal membrane protein that cleaves the beta-glucosidic linkage of glycosylceramide, an intermediate in glycolipid metabolism. Mutations in this gene cause Gaucher disease, a lysosomal storage disease characterized by an accumulation of glucocerebrosides. A related pseudogene is approximately 12 kb downstream of this gene on chromosome 1. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jan 2010]

Uniprot Description

GBA: Defects in GBA are the cause of Gaucher disease (GD); also known as glucocerebrosidase deficiency. GD is the most prevalent lysosomal storage disease, characterized by accumulation of glucosylceramide in the reticulo-endothelial system. Different clinical forms are recognized depending on the presence (neuronopathic forms) or absence of central nervous system involvement, severity and age of onset. Defects in GBA are the cause of Gaucher disease type 1 (GD1); also known as adult non-neuronopathic Gaucher disease. GD1 is characterized by hepatosplenomegaly with consequent anemia and thrombopenia, and bone involvement. The central nervous system is not involved. Defects in GBA are the cause of Gaucher disease type 2 (GD2); also known as acute neuronopathic Gaucher disease. GD2 is the most severe form and is universally progressive and fatal. It manifests soon after birth, with death generally occurring before patients reach two years of age. Defects in GBA are the cause of Gaucher disease type 3 (GD3); also known as subacute neuronopathic Gaucher disease. GD3 has central nervous manifestations. Defects in GBA are the cause of Gaucher disease type 3C (GD3C); also known as pseudo-Gaucher disease or Gaucher-like disease. Defects in GBA are the cause of Gaucher disease perinatal lethal (GDPL). It is a distinct form of Gaucher disease type 2, characterized by fetal onset. Hydrops fetalis, in utero fetal death and neonatal distress are prominent features. When hydrops is absent, neurologic involvement begins in the first week and leads to death within 3 months. Hepatosplenomegaly is a major sign, and is associated with ichthyosis, arthrogryposis, and facial dysmorphism. Perinatal lethal Gaucher disease is associated with non-immune hydrops fetalis, a generalized edema of the fetus with fluid accumulation in the body cavities due to non-immune causes. Non-immune hydrops fetalis is not a diagnosis in itself but a symptom, a feature of many genetic disorders, and the end-stage of a wide variety of disorders. Defects in GBA contribute to susceptibility to Parkinson disease (PARK). A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features. Belongs to the glycosyl hydrolase 30 family. 3 isoforms of the human protein are produced by alternative splicing.

Protein type: Glycan Metabolism - other glycan degradation; Hydrolase; EC 3.2.1.45; Lipid Metabolism - sphingolipid

Chromosomal Location of Human Ortholog: 1q21

Cellular Component: lysosomal lumen; lysosomal membrane

Molecular Function: protein binding; receptor binding; glucosylceramidase activity

Biological Process: glucosylceramide catabolic process; regulation of water loss via skin; negative regulation of MAP kinase activity; sphingolipid metabolic process; skin morphogenesis; response to estrogen stimulus; negative regulation of inflammatory response; response to glucocorticoid stimulus; carbohydrate metabolic process; negative regulation of interleukin-6 production; sphingosine biosynthetic process; ceramide biosynthetic process; glycosphingolipid metabolic process; response to testosterone stimulus; positive regulation of protein amino acid dephosphorylation; response to pH

Disease: Gaucher Disease, Type Ii; Dementia, Lewy Body; Parkinson Disease, Late-onset; Gaucher Disease, Type Iiic; Gaucher Disease, Perinatal Lethal; Gaucher Disease, Type Iii; Gaucher Disease, Type I

Research Articles on GBA

Similar Products

Product Notes

The GBA gba (Catalog #AAA9202426) is an Antibody produced from Rabbit and is intended for research purposes only. The product is available for immediate purchase. The immunogen sequence is 337-365. The GC Antibody (Center) reacts with Human, mouse (Predicted Reactivity: Bovine, Pig) and may cross-react with other species as described in the data sheet. AAA Biotech's GC can be used in a range of immunoassay formats including, but not limited to, Immunohistochemistry (IHC) - Paraffin - Leica, Flow Cytometry (FC/FACS), Western Blot (WB), ELISA. IHC-P-Leica~~1:500 FC~~1:25 WB~~1:1000. Researchers should empirically determine the suitability of the GBA gba for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "GC, Polyclonal Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.

Precautions

All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.

Disclaimer

Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.

Item has been added to Shopping Cart

If you are ready to order, navigate to Shopping Cart and get ready to checkout.

Looking for a specific manual?
Request a Manual

Request more Information

Please complete the form below and a representative will contact you as soon as possible.

Request a Manual

Please complete the form below and a representative will contact you as soon as possible.

Request a Quote

Please complete the form below and a representative will contact you as soon as possible.